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Abstract 
There is a large amount of information in brightfield images that was previously inaccessible using 
traditional microscopy techniques. This information can now be exploited using machine learning 
approaches for both image segmentation and the classification of objects. We have combined these 
approaches with a label-free assay for growth and differentiation of leukemic colonies, to generate a 
novel platform for phenotypic drug discovery. Initially a supervised machine learning algorithm was 
used to identify in-focus colonies growing in a 3D methylcellulose gel. Once identified, unsupervised 
clustering and principle component analysis of texture based phenotypic profiles were applied to 
identify novelgroup similar phenotypes. In a proof of concept study we successfully identified a novel 
phenotype induced by a compound that is currently in clinical trials for the treatment of leukaemia. 
We believe that our platform will be of great benefit for the utilization of patient-derived 3D cell 
culture systems for both drug discovery and diagnostic applications. 
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Abbreviations 
3D  Three dimensional 
AML  Acute myeloid leukaemia 
BET   Bromodomain and extraterminal domain 
BF  Brightfield 
CFC  Colony forming cell 
DMSO  Dimethyl sulfoxide 
GFP  Green Fluorescent Protein 
H3  Histone three 
IMDM  Iscove’s Modified Dulbecco’s Medium 
LSC  Leukemic stem cell 
MLL  Mixed lineage leukaemia 
PCA  Principle component analysis 
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Introduction 
As a model disease for understanding cancer biology, leukaemia has been exceptionally revealing 
1
. 
Leukemic stem cells (LSCs) driving acute myeloid leukaemia (AML) were the first described cancer 
stem cell 
2
, ultimately leading to the more generalized 'cancer-stem-cell hypothesis'. Various 
translocations involving the mixed lineage leukaemia (MLL) gene lead to multiple haematological 
malignancies, including AML, and are often associated with a poor prognosis. MLL is a DNA-binding 
protein and epigenetic regulator that methylates histone H3 lysine 4 
3
. When present as a 
leukaemogenic fusion protein MLL has been shown to bind to the promoters of the Hoxa9 and Meis1 
genes and promote be associated with histone modification 4.   When grown in vitro, LSC colonies 
display graded phenotypes depending on the initiating mutation   
5,6
. Looser colonies are surrounded 
by a spectrum of more differentiated blast-like cells, while denser colonies contain more 
undifferentiated cells 
7
. These phenotypes are potentially clinically relevant as it has been shown that 
colony morphology is correlated with the disease prognosis in mice 
6
. Because the phenotype is easily 
visualized, it is possible to use image based screening to identify agents that can drive leukaemic cells 
towards a more benign, differentiated phenotype. We have developed a method for high-throughput, 
high-content screening of live colonies cultured and imaged in 3D. To validate the sensitivity of our 
approach to variations in genetic background we performed a pilot screen in three different cell lines. 
This allowed comparison of effects between human and mouse species and, in mouse, between 
primary cells transformed by different oncogenes. 
Colony formation assays are typically performed in 6-well plates and scored manually by a researcher. 
After initial isolation, cells are mixed with cytokine-containing semi-solid methylcellulose-based media 
formulated to promote leukaemic colony growth in three dimensions through proliferation and 
differentiation 
8
. The methylcellulose colony forming cell (CFC) assay 
9
, is a preferred in vitro assay 
used in the study of primitive hematopoietic cells, and cells can readily be recovered from 
methylcellulose for further phenotypic and molecular characterization. Due to observed auto-
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fluorescence of the growth gel (the methylcellulose scaffold and growth media mix), direct fluorescent 
imaging of GFP expressing cell colonies in situ could notcannot be utilized for our growth conditions.   
These colony forming assays are therefore low throughput, susceptible to bias due to manual scoring 
and generally unsuitable for arrayed chemical or genetic screening. Being able to employ these 3D 
assays for automated high throughput screening of peturbagens would clearly be advantageous, in 
both probing for mechanistic insights relating to disease biology and unearthing new therapeutic 
agents. In addition, the ability to perform high content screening for agents that are not simply 
preventing colony growth toxic but could drive colonies from a dense to loose phenotype would have 
added utility for drug discovery 
10
. 
Brightfield (BF) images contain rich texture information which, until recently, was inaccessible to 
automated image analysis 
11–13
. BF imaging of live cells also has several advantages over fluorescent 
imaging. Being label-free, there is no need to modify the cells with either a fluorescent protein 
expression cassette or the addition of dyes that could perturb normal cell function. Quantification of 
label-free BF images of colonies in situ would also support both short- and long-term live cell kinetic 
studies. We have previously been successful in developing a simple machine learning based analysis 
pipeline that could determine colony number and size from BF images 14. Here, we investigate 
whether a similar approach could be employed in a screening campaign, not only to count and size 
colonies, but additionally to use the texture information to phenotypically profile colonies and 
potentially identify compounds that can induce novel phenotypes.  
Materials and Methods 
See also table 1 for a summary of the screen protocol 
Colony Culture 
THP-1 cells were cultured at 500,000 cells/ml in RPMI-1640 GlutaMAX containing 10% FBS, 100 U/ml 
penicillin, and 100 μg/ml streptomycin.  
Formatted: Font: Not Bold
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MMA (MLL-AF9KI/+ cells): foetal liver haematopoietic cells were extracted from a E14.5 MLL-AF9KI/+ 
embryo (MLL-AF9
KI/+
 mice 
15
 were obtained from The Jackson Laboratory). After c-Kit enrichment using 
MACS LS columns (Miltenyi Biotec), cells were serially replated every 6 d in MethoCult M3231 
(STEMCELL Technologies) supplemented with 20ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml 
GM-CSF. After 3 rounds of plating, cells were cultured at 300,000 cells/ml in IMDM containing 10% 
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin, supplemented with SCF, IL-3, and IL-6.  
MMH (Meis1/Hoxa9 cells): foetal liver haematopoietic cells were extracted from a E14.5 C57Bl/6 
embryo. Following c-Kit enrichment using MACS LS columns (Miltenyi Biotec), cells were transduced 
with MSCV-Meis1a-puro and MSCV-Hoxa9-neo retroviruses as per 14. Following selection for 
puromycin/neomycin co-resistance, cells were serially replated every 6 days in MethoCult M3231 
(STEMCELL Technologies) supplemented with 20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 and 10 ng/ml 
GM-CSF. After 3 rounds of plating, cells were cultured at 200,000 cells/ml in IMDM containing 10% 
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin, supplemented with SCF, IL-3, and IL-6.  
Animal experimentation complied with local and national requirements (UK Animals Act 1986) 
For methylcellulose medium, 20 ml IMDM (Life Technologies) was added to 80 ml MethoCult 3231 
(STEMCELL Technologies, Catalog #03231), vortexed, and allowed to settle. For primary murine cell 
lines, the methylcellulose was supplemented with cytokines 20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6 
and 10 ng/ml GM-CSF. No antibiotics were added. Cells (THP-1 cells, MLL-AF9
KI/+
 foetal liver cells, or 
murine foetal liver transformed with Meis1 and Hoxa9 retroviruses) were suspended in IMDM and 
added to the prepared methylcellulose at a ratio of 1:9. The mixture was vortexed and allowed to 
settle. Compounds were added as a single dose. 5 μl of 2.1% test drug compound was pipetted into 
the centre of each well of a 96-well non-tissue culture treated edge plate (Thermo Scientific, Cat. # 
267313) with a CyBio FeLix. Subsequently, 100 μl of pre-mixed methylcellulose containing 400 cells 
(THP-1) or 600 cells (MLL-AF9
KI/+
 foetal liver cells, or murine foetal liver transformed with Meis1 and 
Hoxa9 retroviruses) was syringed into each well (using BD Microlance 3 18 Gauge 1.5” needles, 
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resultant drug compound concentration 0.1%). The plate was vortexed, and the side troughs and 
unused wells were half filled with PBS (Sigma) to prevent edge effects due to uneven evaporation. 
Plates were incubated at 37°C 5% CO2 (day 0), and then scanned on day 6 (murine cells), or day 9 (THP-
1 cells).  
Imaging, image and data analysis 
Images were acquired at 37°C 5% CO2 on an Operetta high content microscope (Perkin Elmer) 
equipped with a live cell chamber. The imaging pattern for plates consisted of a snaking pattern across 
columns beginning with the top left gel containing well (B2), down to B7, across to C7 up to C2 and so 
on. In each well the imaging pattern began with the middle field and followed a snaking pattern 
beginning at the top left field, across rows and avoiding imaging of the central field twice. We choose 
9 fields of view to maximise well coverage at 10 X magnification while avoiding the well edges. The 
edge of each of the wells had a texture that the algorithm sometimes identified as a colony and was 
therefore best to avoid. After testing various z-stack options during assay development focal planes 
separated by 150 μm were chosen to avoid repeated counting of the same colonies. Above a height of 
600 μm there were no colonies found and plate scan times were unnecessarily increased. 
Image and numerical data analysis 
Image and subsequent numerical analysis was performed using a variety of software tools: 
 Image analysis was performed in Columbus 2.7.1 (Perkin Elmer) was used for the initial image analysis 
step by manually training the “Find texture region” PhenoLogic machine learning  module to find two 
classes of texture regions in brightfield images. One class contained in-focus colonies (texture A) and 
the other class contained background and out of focus colonies (texture B). Texture A was then split 
into discrete objects, the outer border was shrunk by 6 pixels and any holes were filled. Objects 
greater than 2000 µm
2
 were then considered as colonies and morphology and texture properties were 
calculated using the “Calculate morphology properties” and “Calculate texture properties” modules. 
Formatted: Underline
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Well level aggregated data and Colony data data for individual colonies including morphology and 
texture features was  exported as separate text files.  
subsequently analysed in Spotfire HCP 7.5.0 (Perkin Elmer informatics) 
http://www.cambridgesoft.com was used for rapid initial visualization of the colony count data as 
plate heatmaps at colony and well level and scatterplots at well level for quality control purposes. 
Wells were tagged for positive and negative controls, compounds and concentration added. 
Hierarchical clustering of aggregated well level data and  (Pprinciple Ccomponent Aanalysis 
16
) was 
performed using the built in HCP tools in the software. Principal components and tagged data at the 
well level were exported as text files for further plotting in Python.  
, HC StratoMineR, (Core Life Analytics) www.corelifeanalytics.com was used for (for hit calling of well 
level data based solely on colony number 
17
). All p-values were calculated using the z-test based on 
negative controls with a median estimator with a p-value of <0.0001 considered significant. 
and Python www.python.org  www.python.org was used for plotting of all data, except dose response 
curves. Although not necessarily required for the analysis Python was used so as to maintain 
consistent formatting of figures across the manuscript figures. (all plotting, Python was also used to 
calculate the Z-score normalization and perform the hierarchal clustering shown in figure 4 with: 
sns.clustermap, method='average', metric='cosine').  
 
All p-values were calculated using the z-test with a p-value of <0.0001 considered significant. 
Results 
Supervised machine learning-based segmentation of colonies in three dimensions. 
The following automated image acquisition parameters were developed to enable optimal label-free 
imaging of colonies grown in a 96-well plate while avoiding common pitfalls of assay miniaturization. 
The imaging pattern avoided issues with both imaging the well wall (figure 1a) and identifying the 
Formatted: Underline
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same colony in more than one focal plane (figure 1b). Due to their relatively larger size, the number of 
objects per well of a 96-well plate is limited when measuring colonies rather than cells. To maximise 
image coverage while minimising the time taken for imaging each plate, we employed a 10 X 
objective. This resulted in flatter illumination across fields than the 2 X lens but did result in more 
colonies that were clipped by the edge of the field (figure 1c). Nine fields of view were imaged in each 
well of the 96-well assay plate (figure 1a) covering approximately 50% of the well, with each field 
acquired at five focal planes each separated by 150 µm (figure 1b). All images were subsequently 
segmented using an algorithm (supervised texture segmentation module in the Columbus image 
analysis software) that had previously been trained on an independent training set 
14
. We tested the 
algorithm on three independent cell lines: a human AML (M5) cell line harboring a MLL-AF9 
translocation (THP-1 cells); cells obtained from a mouse (MLL-AF9
KI/+
) with a genomic rearrangement 
leading to expression of the MLL-AF9 fusion protein (further referred to as MMA cells); and a primary 
mouse cell line containing retroviral constructs that overexpress Meis1 and Hoxa9 (further referred to 
as MMH cells), each of which display differences in size and number of colonies. Upon visual 
inspection the segmentation algorithm performed equally well in identifying colonies grown from each 
cell line (figure 1d-f). As a positive control for compound addition to each plate we used iBET 18, a 
known inhibitor of leukemic cell growth and colony formation 
19
. In our assay, iBET proved effective at 
inhibiting the growth of all three cell lines (figure 1g-i). 
Epigenetic tool compound library 
Abnormal epigenetic regulation of gene expression has been implicated as potentially causative in 
several types of myeloid malignancies 
20
. We therefore employed the high quality epigenetic tool 
compound library from the Structural Genomics Consortium (SGC) 
21
 to map which epigenetic 
regulators are involved in colony growth and differentiation across the three different leukaemic cell 
lines. The compounds used are listed in table 2, along with their plate location and known targets. A 
six point dose response was performed starting at 10 µM with a 1 in 5 dilution at each step (giving: 10 
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µM; 2 µM; 400 nM; 80 nM; 16 nM; and 3.2 nM). Although SGC do not recommend using their 
compounds at concentrations higher than 1 µM we had previously observed that in semi-solid 
methylcellulose medium our positive control iBET was only effective at concentrations approximately 
10 fold higher than in liquid culture (unpublished data). We therefore began the dose response at 10 
µM. A  simple visual schematic summary of the screening experimental design is provided protocol is 
shown in table 1, with more detailed procedures inin the materials and methods section. 
 
Digitized colonies: size, number and location 
There was almost complete ablation of colonies in the positive control wells for each cell line (example 
plates shown in figure 2a-c, with iBET added to first 4 wells of rows 2 and last 3 wells of row 11). 
Compounds displaying toxicity ablating colony formation in all three cell lines are also plainly visible 
(figure 2a-c) at the highest concentration used (10 µM). At this concentration the lack of colonies is 
most likely due to toxicity due to the complete lack of cells found after manual inspection of the full 
resolution images. Colony location and size are clearly recapitulated by the segmentation algorithm 
(figure 2d-f). Visualizing the performance of the algorithm as an entire digital plate gave added 
confidence of accurate measurement of colony number and size. 
Quantification of total number of colonies across all plates in the screen shows several compounds to 
be toxicreduce CFC number at lower concentrations (figure 3a). There are no obvious edge effects on 
colony size or number in the outer wells of the plate. There appears to be a general reduction in CFC 
numbers, possibly due to a generally toxic effect of the compounds at the highestr concentrations, 
most apparent in the MMH cell line at 10 µM (figure 3b). Surprisingly there is also a single compound 
(GSK-LSD1) that increases colony number across a range of concentrations (figure 3a and effect size 
shown in 3b). Z-prime (Z’) scores based on colony number are excellent for THP-1 (0.57) and for MMH 
(0.54) cell lines but only -0.52 for the MMA cell line (calculated on 42 positive and 60 negative wells 
spread across 6 plates for each cell line). The reduced Z’ for this primary cell line is due to increased 
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overall noise in the measurements because of 1) the lower colony numbers leading to reduced 
number of colonies quantified, and 2) the greatly increased colony size which results in more frequent 
colony clipping. This is also reflected in called hits based on a reduction in colony number. THP-1 and 
MMH cell lines have almost perfect toxic hit overlap for reduction of colony numbers (table 23, all 
with a p-value < 0.0001 and dose response curves for overlapping compounds in supplemental figure 
1). Most of the hits are at the 10 µM concentration. If compounds with a potency below 10 µM are 
considered, only LAQ824 and JQ1 remain. JQ1 is clearly potent down to 2 µM with an IC50 of 1.6 µM 
for THP-1 derived colonies and 0.9 µM for MMH derived colonies. andJQ1 has a similar chemical 
structure to iBET 
22
, also targeting bromodomains. Far more potent however is LAQ824, killing colonies 
down to 80 nM in both specieswith IC50s of 65 nM for THP-1 and 20 nM for MMH derived colonies. 
The MMA cell line displayed no statistically significant hits at any concentration. 
 
Unsupervised clustering and PCA analysis identify novel colony phenotypes 
Although we had discovered clear toxic hits based on a reduction in colony number, ultimately our 
goal was to find compounds which induce differentiation within the leukemic colonies, ideally 
resulting in a less aggressive clinical phenotype and potentially having more specificity (with fewer side 
effects than a toxic compound that indiscriminately kills proliferating stem cells). To this end we 
performed morphology and texture analysis to give 21 further parameters describing each colony 
(examples in figure 4a). Well level data for the entire screen was then further analysed usingwith a 
hierarchicaln unsupervised clustering algorithm (figure 4b). Wells containing colonies from the same 
cell line largely cluster together, demonstrating a specific morphology profile for colonies derived from 
each cell type. Where there is intermingling of profiles from different cell lines, most of these wells 
had been treated either with the iBET positive control (green) or a compound that had a toxic effect 
atreduced colony number at a particular dose (red). After treatment with a toxic compound that 
affects colony number, wells containing affected colonies cluster together, rather than with their own 
Formatted: Font: Bold
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genotype. This indicates that the phenotypic effect elicited by the compound is stronger than the 
original phenotypic similarity due to the genetics of each cell line. 
To investigate the presence of potentially novel phenotypes, colony morphology and texture was 
further analysed by principle component analysis (PCA). PCA was applied to the entire dataset, 
containing all cell lines and compound concentrations. The first three principal components (PC1, 2 
and 3) respectively capture 48%, 16% and 12% of the variance in the data. In this PCA space a clear 
separation of positive (green) and negative (blue) controls can be seen, particularlyespecially for the 
THP-1   and MMH cell lines (figure 5 a and c). This separation is not as clear for the MMA derived 
colonies (figure 5b). In all cases the majority of compounds (yellow) are found clustering together with 
the DMSO controls having no effect. Many compounds are found in the same space as the positive 
controls (group i in figure 5 a-c). These compounds overlap exactly with the toxic hits based on a 
reduction in colony number (LAQ824, PFI-1, JQ1, GSK J4, NVS-1, OLAPARIB, Bromosporine and CL994 
in both THP-1 and MMH cell lines). As was the case for colony number, when only considering 
compounds at concentrations less than 10 µM, we are again left with JQ1 and LAQ824 and in the case 
of the THP-1 cell line also PFI-1. Most interestingly a single compound, GSK-LSD1 (at concentrations 
ranging from 10 µM to 16 nM) occupies PCA space orthogonal to the positive and negative controls 
(figure 5 a and c, group ii), and was not previously called as a hit based on a reduction in colony 
number. Visual inspection of this phenotype shows colonies that have differentiated into single cells. 
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Discussion 
Due to the high failure rate in target based drug discovery approaches 
23
 there is a need for renewed 
emphasis on phenotypic based approaches 
24
 that recognise the complexity of the biology involved 
10
. 
Recent advances in imaging, cell culture and genetic engineering technologies 
25
, combined with 
advances in machine learning 26,27 are converging to facilitate a high throughput renaissance in 
empirical drug discovery using more complex and relevant cell-based models of disease. Here, we 
present a simple image based screening methodology that relies on a complex but commercially 
available analysis pipeline. Our objective was not to come as close as possible to ground truth 
measurements or improve the error rate of manual counting,.  but toOur aim was  be able to increase 
assay throughput while readily quantifying a phenotypic difference. In this study we have used a 
machine learning approach to automate the quantification of, using a label-free 3D methylcellulose 
colony formation assay, to allow classification of compound activityidentifying a novel  
basedphenotype based on their induced morphological profiless. 
BF is less perturbing and faster than fluorescent imaging in multiple channels and thus particularly well 
suited to complex live-cell kinetic and/or 3D assays. Combined with machine learning facilitated 
analysis, BF images provide a rich source of texture and morphology information that can be mined for 
novel phenotypes. Because our segmentation algorithm was texture rather than intensity based and 
trained specifically to only find in-focus colonies this meant we could screen in 3D and overcome the 
issues of uneven illumination across a well due to the gel meniscus. Furthermore, because BF imaging 
is label-free and permits live imaging with minimal genetic or chemical perturbation, the methods 
described here may be beneficial for personalised diagnostic applications using primary patient-
derived cells. We have also used this approach to identify BF imaged liver organoids and in-focus cystic 
embryoid bodies grown in matrigel and stained with DAPI, followed by further nuclear segmentation 
(based on standard methods), estimation of relative cell numbers per cyst and classification of cells 
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based on fluorescent immunohistochemistry labelled markers (data unpublished). Thus, combining BF 
and fluorescent imaging can lead to even richer phenotypes in multiple tissue types and systems. 
In order to identify and segment colonies in a brightfield image it is critical that the colonies do not 
overlap. Typical image analysis strategies for segmenting touching objects in fluorescent images 
include peak intensity and shape or the more recently developed approach by the Horvath lab 28 that 
includes assumptions about nuclear shape and additive pixel intensities of overlapping nuclei. These 
approaches cannot be employed here as the method for identifying the colonies is texture based. This 
is a limitation of our approach and necessitates a lower object density to avoid overlap. 
During initial assay development we found it necessary to use non-tissue culture treated edge plates 
(Nunc Cat. # 267313) both to prevent colonies in contact with the bottom of the plate spreading over 
the plastic and to avoid what was obvious growth retardation in the outer wells, probably due to 
evaporation. As the number of compounds tested in this pilot screen allowed for only the inner 60 
wells of each plate to be used this further avoided any edge effects. However, for scale up compound 
numbers it would be desirable to use all 96-wells in a plate. In this case use of the edge plates would 
be necessary.  
MMA colonies did not display an orthogonal phenotype in PCA space when treated with GSK-LSD1. 
However, manual examination of GSK-LSD1 treated wells in this cell line reveals a similar 
differentiation effect but with a greatly reduced numbers of cells. These cells however had a curious 
elongated morphology (example seen in figure 5b, GSK-LSD1 at 400 nM). Because the cells were 
sparse they were not grouped as colonies by the algorithm and were lost during the size exclusion step 
after image segmentation. This compound has promise as a therapeutic agent, being potent down to 
16 nM and producing the desired differentiation phenotype without an obvious toxic effect based on 
the continued presence of cells (and depending on genotype). Indeed GSK-LSD1 has been through 
phase I clinical trials to assess safety and activity in patients with relapsed AML (under the generic 
name GSK2879552, https://www.gsk-clinicalstudyregister.com/study/200200#ps). Other lysine 
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demethylase targeting inhibitors in the SGC set did not show same phenotype. These inhibitors target 
proteins other than LSD1 (see table 2), which has been identified as the target of GSK-LSD1 
29
. Another 
lysine demethylase identified as a toxic hit reducing colony number is GSK-J4. This compound targets 
the JMJD3, UTX and JARID1B proteins 
30
 and displays effects only at the highest concentration (10 µM) 
in our assay. This difference between compounds targeting separate lysine demethylases could be 
mechanistically informative, pointing to a specific differentiating effect upon LSD1 inhibition. Although 
only showing toxic a reduction in colony formation rather than purely differentiation effects in this 
assay, LAQ824 has also been used in a phase I clinical trial for patients with advanced solid tumours 31 
and has shown activity against myeloma 
32
 and human acute leukaemia 
33
. 
Future scale up of this screening method would require development of a pipetting head and 
automation platform capable of dispensing large amounts of methylcellulose gel containing cells. The 
current analysis pipeline holds enormous potential for repurposing to a variety of other 3D assay 
formats. We expect that future use of machine learning to analyse label-free images will aid in the 
identification of novel leads to treat a variety of diseases and in their initial diagnosis. 
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Figure Legends 
Figure 1. Imaging strategy. Example of brightfield (BF) images showing: (a) approximate well coverage 
of nine tiled BF images avoiding well wall; (b) an example of a single stack both pre- and post-image 
processing; (c) even illumination and varied colony morphology; (d-f) performance of the algorithm 
throughout the gel for each of the cell lines (all images taken from top left field of DMSO negative 
control at the same plate location, well F2); (g-i) action of positive control on colony growth of each 
genotype (9 tiled images shown per cell line, all images taken from plane 1 in either well F2 for DMSO 
or C2 for 10 µM iBET positive control). 
Figure 2. Digitisation of colonies. Tiled BF images showing plane 1 of an entire plate at the highest 
compound concentration for each cell line (a-c) and the performance of the algorithm across the entire 
plate shown as scatterplots (d-f). Row and column numbers are relative to well position in a 96-well 
plate. 
Figure 3. Colony numbers across entire screen. Heatmaps showing effect of compounds while 
maintaining positional information for each plate (a) and the same data displayed as scatterplots (b) 
more clearly displaying the effect size. Data were normalized to the median DMSO value for each cell 
line. 
Figure 4. Hierarchical Clustering of morphological phenotypes. An example brightfield image with 
segmentation and representations of the spot, edge and ridge texture features (a). Clustered heatmap 
of Z-score normalized profiling data (b). Wells containing each cell line are marked pink, dark grey or 
yellow. Compounds are marked in green for iBET positive control, red for toxic hits reducing colony 
number (as per table 3) and the remaining compounds are white. Empty attribute values (coming from 
wells with no colonies to profile) are light grey. 
Figure 5. Orthogonal phenotype in PCA space. Three-dimensional scatter plots of first three principle 
components, plotted for each genotype (a-c) with example brightfield images directly below each plot. 
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Supplemental Figure 1. Dose response curves. 
Dose response curves are shown for all overlapping compounds that significantly reduce colony 
number (as per table 3). A line shows a logistic regression curve was fitted to data for each compound 
and cell line. Single data points for each concentration without replicates are shown as circles with 
inflection points, corresponding to the IC50, shown as triangles.  
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Figure 1. Imaging strategy. Example of brightfield (BF) images showing: (a) approximate well coverage of 
nine tiled BF images avoiding well wall; (b) an example of a single stack both pre- and post-image 
processing; (c) even illumination and varied colony morphology; (d-f) performance of the algorithm 
throughout the gel for each of the cell lines (all images taken from top left field of DMSO negative control at 
the same plate location, well F2); (g-i) action of positive control on colony growth of each genotype (9 tiled 
images shown per cell line, all images taken from plane 1 in either well F2 for DMSO or C2 for iBET positive 
control).  
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Figure 2. Digitisation of colonies. Tiled BF images showing plane 1 of an entire plate at the highest 
compound concentration for each cell line (a-c) and the performance of the algorithm across the entire plate 
shown as scatterplots (d-f). Row and column numbers are relative to well position in a 96-well plate.  
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Figure 3. Colony numbers across entire screen. Heatmaps showing effect of compounds while maintaining 
positional information for each plate (a) and the same data displayed as scatterplots (b) more clearly 
displaying the effect size. Data were normalized to the median DMSO value for each cell line.  
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Figure 4. Hierarchical Clustering of morphological phenotypes. An example brightfield image with 
segmentation and representations of the spot, edge and ridge texture features (a). Clustered heatmap of Z-
score normalized profiling data (b). Wells containing each cell line are marked pink, dark grey or yellow. 
Compounds are marked in green for iBET positive control, red for hits reducing colony number (as per table 
3) and the remaining compounds are white. Empty attribute values (coming from wells with no colonies to 
profile) are light grey.  
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Figure 5. Orthogonal phenotype in PCA space. Three-dimensional scatter plots of first three principle 
components, plotted for each genotype (a-c) with example brightfield images directly below each plot.  
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Supplemental Figure 1. Dose response curves are shown for all overlapping compounds that significantly 
reduce colony number (as per table 3). A line shows a logistic regression curve was fitted to data for each 
compound and cell line. Single data points for each concentration without replicates are shown as circles 
with inflection points, corresponding to the IC50, shown as triangles.  
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Table 1: Protocol Table 
Step Parameter Value Description 
1 Compound addition 5 μl /well To empty 96 well plate, 2.1% 
DMSO 
2 Mix cells and semi-solid media 20 ml/cell line 4000 cells/ml for human, 
6000 cells/ml for mouse 
3 Add cell mix to plates 100 μl/well Manually with syringe 
4 Vortex 5 seconds  
5 Incubation 6 - 9 days 6 days for mouse, 9 days for 
human 
6 Imaging 30 ms/field BF, 37°C and 5% CO2  
7 Image analysis PhenoLogic module Columbus image analysis 
server 
8 Data analysis Well level Hierarchical clustering and 
PCA 
Step Notes 
1 CyBio FeliX, non-tissue culture treated edge plate  
2 Media pre-warmed to 37°C 
3 Side trough and unused wells half filled with PBS 
4 Ensures mixing of compound with media 
6 Operetta microscope 
8 With Spotfire HCP or HC Stratominer 
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Table 2. Compounds used in this study. 
Compound Row Column Protein Family Specific Targets 
iBET         (positive 
control) 
2,3,4,5,5,6,7 2,2,2,2,11,11,11 Bromodomains BRD2, BRD3, 
BRD4, BRDT  
GSK2801 2 10 Bromodomains BAZ2A, BAZ2B 
BAZ2-ICR 2 9 Bromodomains BAZ2A, BAZ2B 
PFI-4 2 8 Bromodomains BRPF1B 
JQ1 2 7 Bromodomains BRD2, BRD3, 
BRD4, BRDT  
PFI-1 2 6 Bromodomains BRD2, BRD3, 
BRD4, BRDT  
LP99 2 5 Bromodomains BRD9, BRD7 
BI-9564 2 4 Bromodomains BRD9, BRD7 
OF-1 2 3 Bromodomains BRPF1, BRPF2, 
BRPF3 
NI-57 3 10 Bromodomains BRPF1, BRPF2, 
BRPF3 
SGC-CBP30 3 9 Bromodomains CREBBP, EP300 
I-CBP112 3 8 Bromodomains CREBBP, EP300 
NVS-CECR2-1 3 7 Bromodomains CECR2 
IOX1 3 6 Lysine demethylase pan-2-OG 
KDOAM25 3 5 Lysine demethylase KDM5 
SGC0946 3, 7 4, 9 Methyltransferase DOT1L 
UNC1999 3 3 Methyltransferase EZH2 
GSK343 4 10 Methyltransferase EZH2 
UNC0638 4 9 Methyltransferase G9a, GLP 
UNC0642 4 8 Methyltransferase G9a, GLP 
A-366 4 7 Methyltransferase G9a, GLP 
GSK-J4 4 6 Lysine demethylase JMJD3, UTX, 
JARID1B 
UNC1215 4 5 Methyl Lysine Binder L3MBTL3 
GSK-LSD1 4 4 Lysine demethylase LSD1 
GSK484 4 3 Arginine deiminases PAD-4 
Bromosporine 5 10 Bromodomains pan-
Bromodomain 
IOX2 5 9 2-oxoglutarate 
dependent oxygenases 
PHD2 
SGC707 5 8 Methyltransferase PRMT3 
PFI-2 5 7 Methyltransferase SETD7 
PFI-3 5 6 Bromodomains SMARCA,PB1 
LLY-507 5 5 Methyltransferase SMYD2 
BAY-598 5 4 Methyltransferase SMYD2 
A-196 5 3 Methyltransferase SUV420H1/H2 
OICR-9429 6 10 WD40 repeat WDR5 
LAQ-824 6 9 Histone deacetylases - 
OLAPARIB 6 8 DNA repair PARP 
C-646 6 7 Histone 
acetyltransferases 
p300/CBP 
CL-994 6 6 Histone deacetylases HDAC 1, 2, 3, 
and 8 
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IOX-2 6 5 2-oxoglutarate 
dependent oxygenases 
PHD2 
I-BRD9 6 3 Bromodomains BRD9 
GSK-J1 7 3 Lysine demethylase JMJD3, UTX, 
JARID1B 
DMSO            
(negative control) 
2,3,4,   
6,7,7,7,7,7,7 
11,11,11,2,2,4,5,  
6,8,10 
- - 
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Table 3. Hits based on a reduction in colony numbers (p<0.0001) 
Cell 
line 
Species Onco-
gene 
10 uM 2 uM 400 nM 80 nM 16 
nM 
3.2 
nM 
THP-1 human MLL-AF9 LAQ824, PFI-1, 
JQ1, GSK J4, NVS-
CECR2-1, 
OLAPARIB, 
Bromosporine 
LAQ824, 
JQ1  
LAQ824 LAQ824 - - 
MMA mouse MLL-AF9 - - - - - - 
MMH mouse Meis1/ 
Hoxa9 
LAQ824, PFI-1, 
JQ1, GSK J4, NVS-
CECR2-1, 
OLAPARIB, 
Bromosporine, 
CL994 
LAQ824, 
JQ1  
LAQ824 LAQ824 - - 
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